Page last updated: 2024-12-06

10,11-dihydrocarbamazepine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

10,11-dihydrocarbamazepine is a metabolite of carbamazepine, an anticonvulsant drug used to treat epilepsy and bipolar disorder. It is formed in the body by the reduction of carbamazepine. 10,11-dihydrocarbamazepine is also an anticonvulsant, but it has a shorter duration of action than carbamazepine. It is not currently marketed as a drug but is studied for its potential therapeutic effects. Research on 10,11-dihydrocarbamazepine explores its pharmacological activity, metabolism, and potential for therapeutic use. It is of interest because of its unique pharmacological profile and potential to improve the treatment of epilepsy and other neurological disorders.'

Cross-References

ID SourceID
PubMed CID19099
CHEMBL ID41543
SCHEMBL ID1744688
MeSH IDM0153044

Synonyms (53)

Synonym
3564-73-6
OPREA1_404143
EU-0076522
brn 0196969
10,11-dihydro-5h-dibenz(b,f)azepine-5-carboxamide
einecs 222-649-0
10,11-dihydrocarbamazepine
5h-dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-
gp 26-301
10,11-dihydrocarbamazepine, 99%
CHEMBL41543 ,
5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
AKOS000577095
ec017va9fr ,
unii-ec017va9fr
4-20-00-03905 (beilstein handbook reference)
FT-0607181
bdbm50446087
10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide
10,11-dihydro carbamazepine
carbamazepine impurity a [ip]
gp-26-301
dihydrocarbamazepine
carbamazepine impurity a [ep impurity]
10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide
SCHEMBL1744688
5h-dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-
PHNLCHMJDSSPDQ-UHFFFAOYSA-N
10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide #
dibenzo[b,f]azepine, 10,11(5h)-dihydro-5-carbamyl-
STL450943
mfcd00005072
DTXSID90189151
SR-01000312724-1
sr-01000312724
10,11-dihydrocarbamazepine, analytical standard
ZB1063
carbamazepine impurity a, european pharmacopoeia (ep) reference standard
10,11-dihydro-5h-dibenzo[b,f]-azepine-5-carboxamide (10,11-dihydro-carbamazepine)
10,11-dihydro-5h-dibenzo(b,f)azepine-5-carboxamide
BCP08934
EX-A3334
gp 26-301;gp-26-301;gp26-301
C74834
Q27277101
A874560
AB92443
AS-76473
carbamazepine impurity a
CS-0020282
HY-B2124
carbamazepin-10,11-dihydro
carbamazepin-10,11-dihydro 100 microg/ml in acetonitrile
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2X purinoceptor 4Homo sapiens (human)IC50 (µMol)100.00000.15602.93526.1000AID1064727
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
regulation of ruffle assemblyP2X purinoceptor 4Homo sapiens (human)
tissue homeostasisP2X purinoceptor 4Homo sapiens (human)
regulation of sodium ion transportP2X purinoceptor 4Homo sapiens (human)
response to ischemiaP2X purinoceptor 4Homo sapiens (human)
signal transductionP2X purinoceptor 4Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 4Homo sapiens (human)
negative regulation of cardiac muscle hypertrophyP2X purinoceptor 4Homo sapiens (human)
neuronal action potentialP2X purinoceptor 4Homo sapiens (human)
sensory perception of painP2X purinoceptor 4Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 4Homo sapiens (human)
positive regulation of prostaglandin secretionP2X purinoceptor 4Homo sapiens (human)
response to ATPP2X purinoceptor 4Homo sapiens (human)
monoatomic ion transmembrane transportP2X purinoceptor 4Homo sapiens (human)
response to fluid shear stressP2X purinoceptor 4Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 4Homo sapiens (human)
endothelial cell activationP2X purinoceptor 4Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationP2X purinoceptor 4Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processP2X purinoceptor 4Homo sapiens (human)
behavioral response to painP2X purinoceptor 4Homo sapiens (human)
response to axon injuryP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 4Homo sapiens (human)
regulation of chemotaxisP2X purinoceptor 4Homo sapiens (human)
sensory perception of touchP2X purinoceptor 4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2X purinoceptor 4Homo sapiens (human)
membrane depolarizationP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium ion transportP2X purinoceptor 4Homo sapiens (human)
regulation of cardiac muscle contractionP2X purinoceptor 4Homo sapiens (human)
relaxation of cardiac muscleP2X purinoceptor 4Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 4Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 4Homo sapiens (human)
cellular response to zinc ionP2X purinoceptor 4Homo sapiens (human)
cellular response to ATPP2X purinoceptor 4Homo sapiens (human)
apoptotic signaling pathwayP2X purinoceptor 4Homo sapiens (human)
positive regulation of microglial cell migrationP2X purinoceptor 4Homo sapiens (human)
positive regulation of endothelial cell chemotaxisP2X purinoceptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
purinergic nucleotide receptor activityP2X purinoceptor 4Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 4Homo sapiens (human)
signaling receptor bindingP2X purinoceptor 4Homo sapiens (human)
copper ion bindingP2X purinoceptor 4Homo sapiens (human)
protein bindingP2X purinoceptor 4Homo sapiens (human)
ATP bindingP2X purinoceptor 4Homo sapiens (human)
zinc ion bindingP2X purinoceptor 4Homo sapiens (human)
identical protein bindingP2X purinoceptor 4Homo sapiens (human)
cadherin bindingP2X purinoceptor 4Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
lysosomal membraneP2X purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 4Homo sapiens (human)
membraneP2X purinoceptor 4Homo sapiens (human)
cell junctionP2X purinoceptor 4Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 4Homo sapiens (human)
terminal boutonP2X purinoceptor 4Homo sapiens (human)
dendritic spineP2X purinoceptor 4Homo sapiens (human)
cell bodyP2X purinoceptor 4Homo sapiens (human)
perinuclear region of cytoplasmP2X purinoceptor 4Homo sapiens (human)
extracellular exosomeP2X purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1119563Inhibition of recombinant human full length SIRT2 using fluorescent ZMAL as substrate at 50 uM after 4 hrs by homogeneous fluorescent deacetylase assay2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1064727Antagonist activity at human P2X4 receptor expressed in human 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx preincubated for 30 mins followed by ATP addition by Fluo-4 AM dye-based fluorescence assay2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Carbamazepine derivatives with P2X4 receptor-blocking activity.
AID1119562Inhibition of recombinant human N-tagged GST-SIRT1 fusion protein using fluorescent ZMAL as substrate at 50 uM after 4 hrs by homogeneous fluorescent deacetylase assay2012MedChemComm, Mar-01, Issue:3
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1064724Antagonist activity at human P2X4 receptor expressed in human 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx at 100 uM preincubated for 30 mins followed by ATP addition by Fluo-4 AM dye-based fluorescence assay2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Carbamazepine derivatives with P2X4 receptor-blocking activity.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.91 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]